This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Cleo Skin granted FDA Breakthrough Device status
-
Development and External Validation of a Machine Learning-Derived Risk Stratification Score for Metastatic Castration-Resistant Prostate Cancer
Laura Castro-Labrador, et al.. JCO Clinical Cancer Informatics, 2026.
DOI: 10.1200/CCI-26-00054
-
AI driven digital pathology for the 70 gene recurrence signature: Development and validation in early stage breast cancer
Laura J. Van 't Veer, et al..
Weekly News Brief: November 9–13, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of November 9–13, 2026.
This week’s brief covers an FDA Breakthrough Device designation for AI skin cancer pathology, a three-marker machine learning risk score in metastatic castration-resistant prostate cancer, and a digital pathology model that infers the 70-gene MammaPrint score from routine slides.
To learn more about Cleo Skin, read "FDA Grants Breakthrough Device Designation to Cleo Skin for AI-Assisted Skin Cancer Pathology," or see the press release.
For more information on the PROGRESS score, read "Machine Learning–Derived Score May Improve Risk Stratification in Metastatic Castration-Resistant Prostate Cancer," or see the source report in JCO Clinical Cancer Informatics.
To learn more about Digital MammaPrint, read "Digital Pathology Model Infers 70-Gene MammaPrint Score From Routine Slides in Early Breast Cancer," or see the abstract.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.